427 related articles for article (PubMed ID: 18562427)
21. Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to CO2 challenge.
Poma SZ; Merlo-Pich E; Bettica P; Bani M; Fina P; Ziviani L; Milleri S
J Psychopharmacol; 2014 May; 28(5):491-7. PubMed ID: 24108409
[TBL] [Abstract][Full Text] [Related]
22. Diazepam versus alprazolam for the treatment of panic disorder.
Noyes R; Burrows GD; Reich JH; Judd FK; Garvey MJ; Norman TR; Cook BL; Marriott P
J Clin Psychiatry; 1996 Aug; 57(8):349-55. PubMed ID: 8752017
[TBL] [Abstract][Full Text] [Related]
23. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
Greenblatt DJ; Harmatz JS; von Moltke LL; Wright CE; Durol AL; Harrel-Joseph LM; Shader RI
J Pharmacol Exp Ther; 2000 May; 293(2):435-43. PubMed ID: 10773013
[TBL] [Abstract][Full Text] [Related]
24. Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABA(A)/alpha1 receptors.
Rowlett JK; Spealman RD; Lelas S; Cook JM; Yin W
Psychopharmacology (Berl); 2003 Jan; 165(3):209-15. PubMed ID: 12420154
[TBL] [Abstract][Full Text] [Related]
25. Anxiety responses to CO2 inhalation in subjects at high-risk for panic disorder.
Coryell W; Pine D; Fyer A; Klein D
J Affect Disord; 2006 May; 92(1):63-70. PubMed ID: 16527360
[TBL] [Abstract][Full Text] [Related]
26. NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy.
Mirza NR; Larsen JS; Mathiasen C; Jacobsen TA; Munro G; Erichsen HK; Nielsen AN; Troelsen KB; Nielsen EØ; Ahring PK
J Pharmacol Exp Ther; 2008 Dec; 327(3):954-68. PubMed ID: 18791063
[TBL] [Abstract][Full Text] [Related]
27. Alprazolam (Xanax, and others) revisited.
Med Lett Drugs Ther; 2005 Jan; 47(1200):5-7. PubMed ID: 15647704
[TBL] [Abstract][Full Text] [Related]
28. Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines.
Herman JB; Brotman AW; Rosenbaum JF
J Clin Psychiatry; 1987 Oct; 48 Suppl():22-8. PubMed ID: 2889722
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.
de Haas SL; Franson KL; Schmitt JA; Cohen AF; Fau JB; Dubruc C; van Gerven JM
J Psychopharmacol; 2009 Aug; 23(6):625-32. PubMed ID: 18635696
[TBL] [Abstract][Full Text] [Related]
30. Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers.
Bailey JE; Argyropoulos SV; Kendrick AH; Nutt DJ
Depress Anxiety; 2005; 21(1):18-25. PubMed ID: 15782425
[TBL] [Abstract][Full Text] [Related]
31. Alprazolam in the treatment of neurotic anxiety.
Kerry RJ; McDermott CM
Pharmatherapeutica; 1983; 3(7):451-5. PubMed ID: 6142462
[TBL] [Abstract][Full Text] [Related]
32. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
33. Effects of 7.5% CO2 challenge in generalized anxiety disorder.
Seddon K; Morris K; Bailey J; Potokar J; Rich A; Wilson S; Bettica P; Nutt DJ
J Psychopharmacol; 2011 Jan; 25(1):43-51. PubMed ID: 20233897
[TBL] [Abstract][Full Text] [Related]
34. Aspects of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence.
Schoch P; Moreau JL; Martin JR; Haefely WE
Biochem Soc Symp; 1993; 59():121-34. PubMed ID: 7910739
[TBL] [Abstract][Full Text] [Related]
35. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
[TBL] [Abstract][Full Text] [Related]
36. Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans.
Leicht G; Mulert C; Eser D; Sämann PG; Ertl M; Laenger A; Karch S; Pogarell O; Meindl T; Czisch M; Rupprecht R
Biol Psychiatry; 2013 Feb; 73(4):337-44. PubMed ID: 23059050
[TBL] [Abstract][Full Text] [Related]
37. Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one].
Licata SC; Platt DM; Cook JM; Sarma PV; Griebel G; Rowlett JK
J Pharmacol Exp Ther; 2005 Jun; 313(3):1118-25. PubMed ID: 15687371
[TBL] [Abstract][Full Text] [Related]
38. The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety.
Diaper A; Papadopoulos A; Rich AS; Dawson GR; Dourish CT; Nutt DJ; Bailey JE
Hum Psychopharmacol; 2012 Nov; 27(6):540-8. PubMed ID: 23027657
[TBL] [Abstract][Full Text] [Related]
39. Anxioselective anxiolytics: can less be more?
Basile AS; Lippa AS; Skolnick P
Eur J Pharmacol; 2004 Oct; 500(1-3):441-51. PubMed ID: 15464051
[TBL] [Abstract][Full Text] [Related]
40. Strain- and model-dependent effects of chlordiazepoxide, L-838,417 and zolpidem on anxiety-like behaviours in laboratory mice.
Mathiasen LS; Mirza NR; Rodgers RJ
Pharmacol Biochem Behav; 2008 Jul; 90(1):19-36. PubMed ID: 18321566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
